Study for safety and efficacy of fasting therapy of metabolic syndrome

Sichuan Hospital of Integrated Chinese and Western Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•Meet the Global consensus on Metabolic Syndrome of the International Diabetes Alliance, abdominal obesity (waist circumference >=90cm for men and >=80cm for women);
•1. HDL-c (high-density lipoprotein cholesterol) <0.9mmol/L (male) or 1.1mmol/L (female);
•2. TG (triglyceride) >1.7mmol/L;
•3. SBP (systolic blood pressure) >=130mmHg, or DBP (diastolic blood pressure) >=85mmHg;
•4. FPG (fasting blood glucose) 5.6 to 11.1 mmol/L;
•5. 9.0% or greater HbA1C; Participants are informed of this study and volunteered to participate in the study.

•1. type 1 DM or special type DM, or GDM; Serious complications of liver, kidney, brain, heart and other important organs and systems;
•2. participants with other drug trials within the past 3 months; Antibiotics and microecological preparations were taken within 4 weeks;
•3. poor blood glucose control and insulin injection >=30u;
•4. secondary hypertension;
•5. age <18 years and >=70 years;
•6. associated with protein-wasting diseases;
•7. diarrhea or other gastrointestinal diseases within the last 4 weeks; Previous history of gastrointestinal surgery.

发起方

Sichuan Hospital of Integrated Chinese and Western Medicine